Hostname: page-component-586b7cd67f-dsjbd Total loading time: 0 Render date: 2024-11-27T06:44:25.690Z Has data issue: false hasContentIssue false
  • English
  • Français

Olazepine (Zalasta) treatment of residual phenomenology in patients with long-term schizophrenic disorder

Published online by Cambridge University Press:  16 April 2020

G. Hadzi-Angelkovski ,
S. Arsova ,
V. Vujovic ,
N. Simonovski ,
L. Aleksovska  and
M. Stanoevska
G. Hadzi-Angelkovski
Affiliation:
Psychiatric Hospital, Skopje, Macedonia
S. Arsova
Affiliation:
Psychiatric Clinic, Skopje, Macedonia
V. Vujovic
Affiliation:
Psychiatric Clinic, Skopje, Macedonia
N. Simonovski
Affiliation:
Psychiatric Hospital, Skopje, Macedonia
L. Aleksovska
Affiliation:
Medical Ambulance JPAU, Skopje, Macedonia
M. Stanoevska
Affiliation:
DOO KRKA FARMA, Skopje, Macedonia

Abstract

Core share and HTML view are not available for this content. However, as you have access to this content, a full PDF is available via the ‘Save PDF’ action button.
Aim of the work:

To follow the efficiency of Olazepine in chronic patients with long-term schizophrenic disorder in three levels: cognitive functioning, positive persistent hallucinatory-delusive phenomenon and deficiency signs.

Material and methods:

In the research we included 30 patients diagnosed by the ICD 10 with Dg. F 20.5. They were from both sexes, randomly chosen, aged 30-60 treated in an out-patient clinic as well as in the Psychiatric clinic, Skopje. The patients were with long-term treatment with conventional neuro-therapy without any significant results. During the research we included the following psychometric instruments: PANSS scale, BPRS and scale to evaluate cognitive functioning. The patients were evaluated in the beginning of the treatment and after 3 month treatment with Olazepine (Zalasta tablets) in dosages of 5-15mg per day.

Results:

Expected effects on the part of Olazepine in patients with residual schizophrenia on cognitive, hallucinatory-delusive and behavioral field.

Type
Poster Session 1: Antipsychotic Medications
Information
European Psychiatry , Volume 22 , Issue S1: 15th AEP Congress - Abstract book - 15th AEP Congress , March 2007 , pp. S154 - S155
Copyright
Copyright © European Psychiatric Association 2007
Submit a response

Comments

No Comments have been published for this article.